Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 320 people, planned
- Started
- 11 Sept 2025
- Planned end
- 1 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Potassium-Competitive Acid Blocker
- Proton Pump Inhibitor
- Record updated
- 12 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Adults aged ≥18 years
- Both sexes
- Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT)
- No prior eradication therapy
Who cannot take part
- Prior Helicobacter pylori treatment
- Use of antibiotics, proton pump inhibitor, or bismuth in the prior 4 weeks
- Gastric surgery history
- Major organ failure
- Known allergy to study drugs
- Pregnancy or lactation
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in Egypt.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori infection.
The 2 groups in the trial
- B-CAP groupTreatment being tested
Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.
Treatment: Potassium-Competitive Acid Blocker
- PPI groupExisting treatment, for comparison
Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.
Treatment: Proton Pump Inhibitor
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection: A Randomized Controlled Trial
- Criteria questions
- Built from NCT07165444, who can take part
- Record updated
- 12 September 2025